Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:52:03 UTC |
---|
HMDB ID | HMDB0015637 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Vilazodone |
---|
Description | Vilazodone, also known as SB 659746A or HCL, vilazodone, belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. Vilazodone selectively inhibits serotonin reuptake in the central nervous system as well as acting as a partial agonist of 5HT-1A receptors. Vilazodone is a very strong basic compound (based on its pKa). Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Clinical cases of fetal and neonatal exposure to SSRIs and SNRIs have lead to a number of complications including respiratory distress, seizures, and temperature instability. The exact mechanism for how these effects translate to its antidepressant effects are not known, though there is an association between these effects and antidepressive activity. Vilazodone is an antidepressant agent that can used as an alternative for patients who cannot tolerate therapy with other antidepressant classes such as selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. Dosage adjustments are not necessary for patients of different genders or with reduced hepatic and renal function. |
---|
Structure | NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1 InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32) |
---|
Synonyms | Value | Source |
---|
Vilazodona | ChEBI | Vilazodonum | ChEBI | SB 659746a | HMDB | HCL, Vilazodone | HMDB | Hydrochloride, vilazodone | HMDB | 2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) | HMDB | Viibryd | HMDB | Vilazodone HCL | HMDB | Vilazodone hydrochloride | HMDB | 5-(4-(4-(5-Cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide | HMDB |
|
---|
Chemical Formula | C26H27N5O2 |
---|
Average Molecular Weight | 441.5249 |
---|
Monoisotopic Molecular Weight | 441.216475133 |
---|
IUPAC Name | 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide |
---|
Traditional Name | vilazodone |
---|
CAS Registry Number | 163521-12-8 |
---|
SMILES | NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1 |
---|
InChI Identifier | InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32) |
---|
InChI Key | SGEGOXDYSFKCPT-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazinanes |
---|
Sub Class | Piperazines |
---|
Direct Parent | N-arylpiperazines |
---|
Alternative Parents | |
---|
Substituents | - N-arylpiperazine
- 3-alkylindole
- Benzofuran
- Indole
- Indole or derivatives
- 2-heteroaryl carboxamide
- Furoic acid or derivatives
- Tertiary aliphatic/aromatic amine
- Dialkylarylamine
- Aralkylamine
- N-alkylpiperazine
- Substituted pyrrole
- Benzenoid
- Furan
- Pyrrole
- Heteroaromatic compound
- Amino acid or derivatives
- Carboxamide group
- Primary carboxylic acid amide
- Tertiary amine
- Tertiary aliphatic amine
- Nitrile
- Carbonitrile
- Carboxylic acid derivative
- Oxacycle
- Azacycle
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.12 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Vilazodone,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4411.5 | Semi standard non polar | 33892256 | Vilazodone,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4406.5 | Standard non polar | 33892256 | Vilazodone,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 5883.0 | Standard polar | 33892256 | Vilazodone,1TMS,isomer #2 | C[Si](C)(C)N1C=C(CCCCN2CCN(C3=CC=C4OC(C(N)=O)=CC4=C3)CC2)C2=CC(C#N)=CC=C21 | 4402.9 | Semi standard non polar | 33892256 | Vilazodone,1TMS,isomer #2 | C[Si](C)(C)N1C=C(CCCCN2CCN(C3=CC=C4OC(C(N)=O)=CC4=C3)CC2)C2=CC(C#N)=CC=C21 | 4222.8 | Standard non polar | 33892256 | Vilazodone,1TMS,isomer #2 | C[Si](C)(C)N1C=C(CCCCN2CCN(C3=CC=C4OC(C(N)=O)=CC4=C3)CC2)C2=CC(C#N)=CC=C21 | 6132.2 | Standard polar | 33892256 | Vilazodone,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C | 4428.0 | Semi standard non polar | 33892256 | Vilazodone,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C | 4433.6 | Standard non polar | 33892256 | Vilazodone,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C | 5667.6 | Standard polar | 33892256 | Vilazodone,2TMS,isomer #2 | C[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4410.9 | Semi standard non polar | 33892256 | Vilazodone,2TMS,isomer #2 | C[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4368.5 | Standard non polar | 33892256 | Vilazodone,2TMS,isomer #2 | C[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 5633.1 | Standard polar | 33892256 | Vilazodone,3TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C | 4431.5 | Semi standard non polar | 33892256 | Vilazodone,3TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C | 4361.7 | Standard non polar | 33892256 | Vilazodone,3TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C | 5385.8 | Standard polar | 33892256 | Vilazodone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4647.1 | Semi standard non polar | 33892256 | Vilazodone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4611.9 | Standard non polar | 33892256 | Vilazodone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 5863.3 | Standard polar | 33892256 | Vilazodone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(CCCCN2CCN(C3=CC=C4OC(C(N)=O)=CC4=C3)CC2)C2=CC(C#N)=CC=C21 | 4598.8 | Semi standard non polar | 33892256 | Vilazodone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(CCCCN2CCN(C3=CC=C4OC(C(N)=O)=CC4=C3)CC2)C2=CC(C#N)=CC=C21 | 4428.3 | Standard non polar | 33892256 | Vilazodone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(CCCCN2CCN(C3=CC=C4OC(C(N)=O)=CC4=C3)CC2)C2=CC(C#N)=CC=C21 | 6112.0 | Standard polar | 33892256 | Vilazodone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C(C)(C)C | 4862.0 | Semi standard non polar | 33892256 | Vilazodone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C(C)(C)C | 4833.0 | Standard non polar | 33892256 | Vilazodone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=C[NH]C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C(C)(C)C | 5612.4 | Standard polar | 33892256 | Vilazodone,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C(C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4839.2 | Semi standard non polar | 33892256 | Vilazodone,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C(C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 4769.7 | Standard non polar | 33892256 | Vilazodone,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C(C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1 | 5611.5 | Standard polar | 33892256 | Vilazodone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C(C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C(C)(C)C | 5006.0 | Semi standard non polar | 33892256 | Vilazodone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C(C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C(C)(C)C | 4916.3 | Standard non polar | 33892256 | Vilazodone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC2=CC(N3CCN(CCCCC4=CN([Si](C)(C)C(C)(C)C)C5=CC=C(C#N)C=C45)CC3)=CC=C2O1)[Si](C)(C)C(C)(C)C | 5365.8 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Vilazodone GC-MS (Non-derivatized) - 70eV, Positive | splash10-0pb9-1892200000-e80db0623de8c5d5253b | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Vilazodone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 10V, Positive-QTOF | splash10-004l-0100900000-419df74d78f3394907e4 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 20V, Positive-QTOF | splash10-0a6r-0211900000-fc5409d02ddc3a074e29 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 40V, Positive-QTOF | splash10-0ard-0930000000-ca1734ab642c796bbcaf | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 10V, Negative-QTOF | splash10-0006-0000900000-709b81c1b5cb6d2d8c1b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 20V, Negative-QTOF | splash10-0005-1009600000-913d3342fc1dba5181ae | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 40V, Negative-QTOF | splash10-0006-9341100000-d9863664c2546f78ac6b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 10V, Positive-QTOF | splash10-0006-0000900000-fb0afc1a6de498c1d581 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 20V, Positive-QTOF | splash10-002g-0201900000-7049e2907cdc39ce7fa8 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 40V, Positive-QTOF | splash10-0pba-0931100000-c3a86c8646e2eb2feac2 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 10V, Negative-QTOF | splash10-0006-0004900000-f0610bc45efeb8e8cd19 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 20V, Negative-QTOF | splash10-0006-5006900000-70aadc301ad860239f5b | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vilazodone 40V, Negative-QTOF | splash10-00kf-5598400000-9ca429b67adcdbb9ca8b | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|
General References | - Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. [PubMed:12183683 ]
- de Paulis T: Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs. 2007 Mar;10(3):193-201. [PubMed:17351874 ]
- Dawson LA, Watson JM: Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009 Summer;15(2):107-17. [PubMed:19499624 ]
- Howland RH: Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv. 2011 Mar;49(3):19-22. doi: 10.3928/02793695-20110203-98. Epub 2011 Feb 16. [PubMed:21323263 ]
- Traynor K: Vilazodone approved for major depression. Am J Health Syst Pharm. 2011 Mar 1;68(5):366. doi: 10.2146/news110009. [PubMed:21330672 ]
- Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR: A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011 Apr;72(4):441-7. doi: 10.4088/JCP.10m06596. [PubMed:21527122 ]
- Dopheide JA: Vilazodone's comparative merits yet to be demonstrated. Am J Health Syst Pharm. 2012 Sep 15;69(18):1549. doi: 10.2146/ajhp110570. [PubMed:22935936 ]
- Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU: A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013 Aug;17(3):160-9. doi: 10.3109/13651501.2013.794245. Epub 2013 May 29. [PubMed:23578403 ]
|
---|